CORONA Remedies Limited (CORONA) — Announcement | 10 August 2026

10 August 2026 · NSE Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Management reaffirmed FY27 growth targets and highlighted EU-GMP facility progress

🔄 What Changed

22.7% India revenue growth and 33.5% EBITDA growth YoY

🔮 What's Next

15% organic and 25% inorganic growth targets for FY27

💡 Investor Takeaway

The company is on track to achieve 15% organic growth and 20% PAT growth in FY27, supported by chronic therapy expansion and new facility ramp-up.

⚠️ Risks

Depreciation impact from new hormone plant capitalization

CORONA Remedies reported strong Q1 FY27 results with 21.9% YoY revenue growth driven by 22.7% India growth and 33.5% EBITDA growth, supported by 73.4% revenue contribution from chronic therapies and a newly EU-GMP certified women's healthcare facility. Management reaffirmed 15% organic and 25% inorganic growth targets for FY27, with 20% PAT growth guidance, while highlighting margin expansion through product mix and operating leverage despite depreciation pressures from a INR130 crore hormone plant capitalization.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CORONA ✨ Ask AI About This

About CORONA Remedies Limited (CORONA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹12,701.42 CrP/E: 63.8ROE: 26.6%ROCE: 30.1%Div Yield: 0.48%

View full CORONA stock details →

📡 Get AI alerts when CORONA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CORONA — Free

💡 Ask AI about this filing

"How will the 15% organic growth target be sustained beyond Q1?""What is the expected revenue contribution from the new EU-GMP facility in FY28?""How will depreciation impact PAT margins in upcoming quarters?"

Ask AI Free →

📊 More CORONA filings

Announcement — 28 September 2026Corona Remedies Ltd announced that its trading window will close on October 1, 2026, remaining shut ...
🔴 Insider Trading — 19 September 2026Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,485,476; 51,641; and 92...
🔴 Insider Trading — 19 September 2026Sepia Investments Limited, Sage Investment Trust and Anchor Partners sold a combined 2,630,880 share...
🔴 Announcement — 18 September 2026Corona Remedies Ltd announced an analyst and investor meeting scheduled for September 23, 2026 at 2:...
Announcement — 10 September 2026Corona Remedies clarified that recent share volume increases are purely market-driven with no undisc...

See all CORONA filings →

🔥 Also filed on 10 August 2026

TIMKENTimken India LimitedFinancial Results DOMSDOMS Industries LimitedCorporate Action HGSHinduja Global Solutions LimitedFinancial Results SUNDRMFASTSundram Fasteners LimitedFinancial Results AMJLANDAmj Land Holdings LimitedAnnual Report KANSAINERKansai Nerolac Paints LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CORONA files new disclosures

Track CORONA filings, board meetings, and corporate actions. Free email alerts at 5 PM.